Scholarlink

Background <p>In 2005, the first approval study of a&#xa0;preventive quadrivalent human papillomavirus (HPV) vaccine in young women triggered vaccination strategies around the world.</p> Objective <p>We aimed to investigate how successful these vaccination interventions have been in preventing cancer so far.</p> Methods <p>To this end, we reviewed the relevant literature of the past two decades regarding vaccination rates and the subsequent decline in HPV-associated diseases worldwide.</p> Results <p>For various reasons, many countries that offer HPV vaccinations are still missing their goals for primary cancer prevention. In Germany, for example, vaccination rates are completely inadequate, and urologists are not even recognized as vaccinators.</p> Conclusion <p>Cancer prevention through HPV vaccination is zur Hausen’s scientific legacy to the world. However, each country must continuously analyze and combat its specific reasons for failing in HPV vaccination. New HPV vaccines will continue the global success story in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impfung gegen humane Papillomaviren (HPV) zur Krebsvorbeugung

  • 期刊论文

  • 发表日期：

    2025年4月30日

查看全文
  • Julius Benedikt Schneede,
  • Peter Schneede

摘要

Background

In 2005, the first approval study of a preventive quadrivalent human papillomavirus (HPV) vaccine in young women triggered vaccination strategies around the world.

Objective

We aimed to investigate how successful these vaccination interventions have been in preventing cancer so far.

Methods

To this end, we reviewed the relevant literature of the past two decades regarding vaccination rates and the subsequent decline in HPV-associated diseases worldwide.

Results

For various reasons, many countries that offer HPV vaccinations are still missing their goals for primary cancer prevention. In Germany, for example, vaccination rates are completely inadequate, and urologists are not even recognized as vaccinators.

Conclusion

Cancer prevention through HPV vaccination is zur Hausen’s scientific legacy to the world. However, each country must continuously analyze and combat its specific reasons for failing in HPV vaccination. New HPV vaccines will continue the global success story in the future.